GPR89B Inhibitors
GPR89B inhibitors encompass a range of chemical compounds that suppress the activity of GPR89B by regulating ion transport and cellular ionic environments, which the protein is presumed to be sensitive to. Amiloride and its analog Benzamil exert their inhibitory effects by blocking epithelial sodium channels, thus reducing sodium influx that can perturb GPR89B signaling which is possibly tied to sodium ion homeostasis. Similarly, Probenecid, by impeding organic anion transporters, and DIDS, as an anion exchanger inhibitor, shift the ionic balance within the cell, potentially disrupting the electrochemical gradients that GPR89B might monitor, leading to a decrease in its activity. Ouabain and Ethacrynic acid, both acting on different components of the Na-K-Cl cotransport mechanism, and Bumetanide, targeting the Na-K-2Cl cotransporter, manipulate the electrolyte balance, which could result in diminished GPR89B function.
Other inhibitors such as Glibenclamide and Clofilium tosylate impact GPR89B activity by modulating potassium ion channels, altering potassium ion flux, and consequently the ionic landscape GPR89B may be involved in regulating. Calcium influx is affected by Verapamil, a calcium channel blocker, which could lead to indirect inhibition of GPR89B by modifying signaling pathways where calcium acts as a secondary messenger. Tetrodotoxin, targeting voltage-gated sodium channels, could also influence GPR89B activity by changing the intracellular sodium concentration. Collectively, these compounds, through their targeted effects on ion transport and cellular ionic conditions, provide a diversified approach to diminishing the functional activity of GPR89B without directly inhibiting the protein or affecting its expression levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Amiloride, a potassium-sparing agent, acts as an inhibitor of sodium channels. In the context of GPR89B, which is thought to be related to ion transport, amiloride can decrease intracellular sodium levels, thereby potentially affecting the signaling pathways GPR89B is involved with and diminishing its functional activity. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Probenecid is a uricosuric agent that inhibits organic anion transporters, thereby affecting cellular ion concentration balance. This can lead to changes in the transmembrane ion gradients that GPR89B may sense or respond to, indirectly decreasing its activity. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain is an inhibitor of the sodium-potassium ATPase pump. By disrupting the ion gradient, it might influence the cellular environment in a way that diminishes the functional activity of ion-sensitive proteins like GPR89B. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
Niflumic acid is recognized as a blocker of chloride channels. By altering chloride ion flux, it could disturb the electrochemical gradient critical for the functional activity of GPR89B, which may be affected by changes in chloride ion concentration. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide is an inhibitor of the Na-K-2Cl cotransporter. This action on electrolyte balance could indirectly decrease the activity of GPR89B if its function is related to sensing or regulating electrolyte homeostasis. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
Glibenclamide is an ATP-sensitive potassium channel inhibitor. By modulating potassium ion flux, it could have an indirect effect on the functional activity of GPR89B by altering the environment that GPR89B is potentially sensitive to. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker. Diminishing calcium entry into cells could affect various signaling pathways, including those that may involve GPR89B, indirectly leading to decreased activity of the protein. | ||||||
Ethacrynic acid | 58-54-8 | sc-257424 sc-257424A | 1 g 5 g | $90.00 $300.00 | 5 | |
Ethacrynic acid inhibits the Na-K-Cl cotransporter. This could have an indirect effect on GPR89B function by altering sodium and potassium ion levels that may influence GPR89B signaling pathways. | ||||||
Benzamil•HCl | 161804-20-2 | sc-201070 | 50 mg | $195.00 | 1 | |
Benzamil is an amiloride analog that also inhibits epithelial sodium channels. By decreasing sodium ion entry, benzamil can diminish the activity of GPR89B by affecting the ionic environment that GPR89B may be involved in monitoring or regulating. | ||||||
Clofilium tosylate | 92953-10-1 | sc-391228 sc-391228A | 25 mg 100 mg | $437.00 $1040.00 | 1 | |
Clofilium tosylate is a potassium channel blocker. It can indirectly reduce the functional activity of GPR89B by modifying the potassium ion flux, potentially disrupting the ionic balance that GPR89B may play a role in. | ||||||